Keryx renal, cancer news

Keryx restructured and reduced headcount by about 25 (50%) to 25 and will explore opportunities to monetize portions of its technology assets, including partnerships, strategic alliances and creative financing alternatives. Last month, the company's Sulonex sulodexide (KRX-101) missed the primary endpoint in the Phase III SUN-MICRO trial to treat diabetic nephropathy. The company will stop the Phase IV SUN-MACRO trial of the oral heparinoid and about 12 of 20 early-stage cancer trials of perifosine ( KRX-0401), an alkylphosphocholine modulator of Akt and other signal transduction pathways. Keryx will close its offices in San Francisco, Calif., and Memphis, Tenn., and its manufacturing facility in Wisconsin (see BioCentury, March 17). ...